#USA #San Diego #Abzena #Antibody Licensing #Orion Pharmaceuticals

Abzena and Orion: A New Venture in Oncology

In a significant development in the biopharmaceutical sector, Abzena has announced an exclusive commercial license agreement with Orion, enabling Orion to leverage one of Abzena's monoclonal antibodies (mAbs). This antibody has been designed specifically for targeting a cancer that currently represents a substantial unmet clinical need. The collaboration aims to strengthen Orion's extensive pipeline of oncology-focused research and development (R&D) initiatives.

A Collaborative Effort for Innovation

The antibody in question was meticulously developed at Abzena's early-phase R&D facility located in Cambridge, UK. Utilizing Abzena’s proprietary Composite Human Antibody (CHAb™) technology, the company has integrated a rigorous development platform to identify a superior lead candidate. This concentrated methodology involved screening various antibodies for key attributes, such as functionality, safety, and manufacturability. The intent was to pinpoint a lead candidate that mitigates potential risks during downstream development processes, ultimately aiding in clinical outcomes.

To support the manufacturing process, Abzena made use of its innovative AbZelectPRO™ cell line development (CLD) platform. This platform produced a stable and high-yielding manufacturing cell line specifically for the antibody, ensuring that the product can be developed efficiently and effectively.

Insights from Key Personnel

Campbell Bunce, the Chief Scientific Officer of Abzena, expressed enthusiasm about the partnership, noting, "We are delighted to have partnered with Orion on the design and development of our CHAb-designed mAb to support their extensive oncology-focused Research and Development pipeline. Using our uniquely integrated developability approach along with our streamlined AbZelectPRO™ CLD platform, we were able to design a de-risked lead antibody that offers Orion's program the best chances of success in the clinic."

Antti Haapalinna, Vice President of External Science and Partnering at Orion Corporation, echoed this sentiment, stating, "We are very satisfied with the excellent and transparent collaboration and the results it has delivered in our common antibody program." This shared vision illustrates the commitment both companies have towards advancing oncology treatments for patients.

Abzena’s Legacy and Commitment

Abzena boasts over two decades of experience in designing, developing, and manufacturing mAb programs. Their facilities in Cambridge, UK, and San Diego, CA, allow them to support various antibody initiatives. The company is capable of performing downstream process development and Good Manufacturing Practice (GMP) manufacturing activities in the US, with production capacities of up to 2,000 liters.

As a leading end-to-end bioconjugate and complex biologics Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO), Abzena emphasizes streamlined processes and integrated service offerings tailored to meet the unique requirements of its clients. This focus on bespoke strategies aims to assist biotech and biopharma companies in maximizing the potential of their molecules for rapid progression towards commercial success.

About the Companies

About Abzena

Abzena specializes in end-to-end development for bioconjugates and complex biologics, offering comprehensive services from discovery to commercial launch. Their mission centers around de-risking and expediting the development of novel treatments for patients with critical needs. Abzena’s extensive facilities across San Diego, Bristol, PA, and Cambridge, UK, highlight its global operational capability. The company is owned by Welsh, Carson, Anderson & Stowe, a prominent private equity firm.

About Orion

Orion is a Nordic pharmaceutical enterprise known for its commitment to improving health for over a century. The company focuses on researching, developing, and marketing both human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients. With a diverse portfolio encompassing proprietary and generic medicines, Orion targets key therapy areas like oncology and pain management. In 2024, Orion reported net sales amounting to EUR 1,542 million and employed approximately 3,700 professionals dedicated to enhancing well-being worldwide. Orion’s shares are publicly traded on Nasdaq Helsinki.

In conclusion, the partnership between Abzena and Orion not only marks a significant milestone in drug development but also showcases the potential of collaborative efforts in biopharmaceutical innovation aimed at addressing pressing health challenges. Their combined expertise may very well lead to breakthroughs in cancer treatment, offering hope to many patients in need.